[高敏C反应蛋白和白蛋白在评估系统性红斑狼疮患者预后中的价值]

[Value of hsCRP and Alb in Evaluating the Prognosis of Patients with Systemic Lupus Erythematosus].

作者信息

Zhang Tian-Ling, Niu Jia-Feng, Liu Ji-Tao, Hu Tian-Yu, Li Qing

机构信息

Clinical Laboratory, Zibo Muaicipal First Hospital, Zibo 255200, Shandong Province, China.

Clinical Laboratory, Zibo Muaicipal First Hospital, Zibo 255200, Shandong Province, China. E-mail:

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Aug;25(4):1218-1222. doi: 10.7534/j.issn.1009-2137.2017.04.045.

DOI:10.7534/j.issn.1009-2137.2017.04.045

PMID:28823296

Abstract

OBJECTIVE

To study the value of hsCRP and Alb in evaluating the prognosis of patients with systemic lupus erythematosus (SLE).

METHODS

126 SLE patients from January 2011 to January 2016 were enrolled in this study, and their clinical data were collected, including SLEDAI, hsCRP and Alb and complications. The correlation between hsCRP/Alb ratio and SLEDAI after treatment was analyzed. All patients were followed up after discharge, and the prognosis-related factors were analyzed.

RESULTS

After treatment, hsCRP/Alb ratio of patients with SLEDAI 10-14 score was significantly higher than that of 5-9 and 0-4 score(P<0.05). hsCRP/Alb ratio was positively correlated with infection (r=0.574), renal damage (r=0.499) and cardiac injury (r=0.516) (P<0.05), while it demonstrated no correlation with blood system damage, CNS damage and lung injury(P>0.05). after treatment SLEDAI ≥10 score, hsCRP/Alb≥0.05 mg/g and complications significantly correlated with prognosis of patients(P<0.05).

CONCLUSION

hsCRP/Alb correlates with the prognosis of patients with SLE at a certam level.

摘要

目的

探讨超敏C反应蛋白（hsCRP）和白蛋白（Alb）在评估系统性红斑狼疮（SLE）患者预后中的价值。

方法

选取2011年1月至2016年1月期间的126例SLE患者，收集其临床资料，包括SLE疾病活动指数（SLEDAI）、hsCRP、Alb及并发症情况。分析治疗后hsCRP/Alb比值与SLEDAI的相关性。所有患者出院后进行随访，分析预后相关因素。

结果

治疗后，SLEDAI评分为10 - 14分患者的hsCRP/Alb比值显著高于5 - 9分及0 - 4分患者（P<0.05）。hsCRP/Alb比值与感染（r = 0.574）、肾损害（r = 0.499）及心脏损伤（r = 0.516）呈正相关（P<0.05），而与血液系统损害、中枢神经系统损害及肺损伤无相关性（P>0.05）。治疗后SLEDAI≥10分、hsCRP/Alb≥0.05 mg/g及并发症与患者预后显著相关（P<0.05）。